Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

BioCapital

Clinical Catch-Up: February 10-14

It was a very busy week for clinical trial news. Here’s a look.

February 14, 2020

11 min read

Mark Terry

FDA

FDA Speeds Up Examination of 5 Drugs with Priority Review

A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.

February 12, 2020

3 min read

Alex Keown

Policy

Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars

In November 2019, the U.S. Food and Drug Administration (FDA) released new draft guidance that would help generic drug companies bring biosimilars to insulin to the market more quickly. And now there are reports that two of the three primary biopharma companies that sell insulin in the U.S. are trying to change that draft guidance.

February 12, 2020

3 min read

Mark Terry

Drug Development

Genentech, Lilly Fail to Meet Primary Endpoint in Alzheimer’s Trial

DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.

February 10, 2020

2 min read

Mark Terry

Laboratory glassware containing chemical liquid, science research

Pharm Country

Clinical Catch-Up: February 3-7, 2020

Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.

February 7, 2020

5 min read

Mark Terry

Job Trends

Clinical Catch-Up: January 27-31

It was another busy week for clinical trial updates. Here’s a look.

January 31, 2020

7 min read

Mark Terry

BioMidwest

Lilly Eying Upcoming Results from the DIAN-TU Alzheimer’s Trial

The focus of the trial, DIAN-TU-001, is looking at drugs that could possibly change the course of the disease.

January 31, 2020

2 min read

Mark Terry

BioMidwest

Eli Lilly Posts Strong Q4 Growth, Plans to Continue Trajectory in 2020

David Ricks, chairman and chief executive officer of Eli Lilly, said the company is in an exciting period of growth.

January 30, 2020

3 min read

Alex Keown

Drug Development

Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.

January 28, 2020

37 min read

Tracy Lawton

JOBS